Synergistic control of sex hormones by 17β-HSD type 7: A novel target for estrogen-dependent breast cancer

Journal of Molecular Cell Biology

Volumn 7, Issue 6, 2015, Pages 568-579

  Wang, Xiaoqiang ^a   Gérard, Catherine ^a   Thériault, Jean François ^a   Poirier, Donald ^a   Doillon, Charles J ^a   Lin, Sheng Xiang ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

17 hydroxysteroid dehydrogenase type 7; Breast cancer; Steroid enzyme inhibition; Xenograft tumor

Indexed keywords

CYCLIN D1; DYHYDROXYTESTOSTERONE; ESTRADIOL; PROTEIN BCL 2; PROTEIN P21; SEX HORMONE; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 7; TESTOSTERONE DERIVATIVE; UNCLASSIFIED DRUG; 3 (OR 17)-BETA-HYDROXYSTEROID DEHYDROGENASE; ANDROGEN; ANDROSTANOLONE; APOPTOSIS REGULATORY PROTEIN; BCL2 PROTEIN, HUMAN; BIK PROTEIN, HUMAN; CCND1 PROTEIN, HUMAN; CHOLESTEROL; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ESTRADIOL 17BETA DEHYDROGENASE; ESTROGEN; ESTRONE; HSD17B1 PROTEIN, HUMAN; HYDROXYSTEROID DEHYDROGENASE; MEMBRANE PROTEIN; MULTIFUNCTIONAL ENZYME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL DENSITY; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY MECHANISM; TUMOR INVASION; ANTAGONISTS AND INHIBITORS; BLOOD; BREAST TUMOR; CELL CYCLE CHECKPOINT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; MCF-7 CELL LINE; METABOLISM;

17-HYDROXYSTEROID DEHYDROGENASES; ANDROGENS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CHOLESTEROL; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DIHYDROTESTOSTERONE; ESTRADIOL; ESTRADIOL DEHYDROGENASES; ESTROGENS; ESTRONE; FEMALE; G1 PHASE; HUMANS; MCF-7 CELLS; MEMBRANE PROTEINS; MULTIFUNCTIONAL ENZYMES; PROTO-ONCOGENE PROTEINS C-BCL-2; RESTING PHASE, CELL CYCLE;

EID: 84975780447     PISSN: 16742788     EISSN: 17594685     Source Type: Journal    
DOI: 10.1093/jmcb/mjv028     Document Type: Article

References (63)

1. Adams, J., Garcia, M., and Rochefort, H. (1981). Estrogenic effects of physiological concentrations of 5-androstene-3 b, 17b-diol and its metabolism in MCF7 human breast cancer cells. Cancer Res. 41, 4720-4726.
2. Aka, J.A., and Lin, S.X. (2012). Comparison of functional proteomic analyses of human breast cancer cell lines T47D and MCF7. PLoS One 7, e31532.
3. Aka, J.A., Mazumdar, M., and Lin, S.X. (2009). Reductive 17b-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer. Mol. Cell. Endocrinol. 301, 183-190.
4. Aka, J.A., Mazumdar, M., Chen, C.Q., et al. (2010). 17b hydroxysteroid dehydrogenase type 1 stimulates breast cancer by dihydrotestosterone inactivation in addition to estradiol production. Mol. Endocrinol. 24, 832-845.
5. Arnold, A., and Papanikolaou, A. (2005). Cyclin D1 in breast cancer pathogenesis. J. Clin. Oncol. 23, 4215-4224.
6. Ayan, D., Maltais, R., Roy, J., et al. (2012).Anewnonestrogenic steroidal inhibitor of 17b-hydroxysteroid dehydrogenase type I blocks the estrogen-dependent breast cancer tumor growth induced by estrone. Mol. Cancer Ther. 11, 2096-2104.
7. Bellavance, E., Luu-The, V., and Poirier, D. (2009). Potent and selective steroidal inhibitors of 17b-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone. J. Med. Chem. 52, 7488-7502.
8. Breitling, R., Krazeisen, G., Moller, G., et al. (2001). 17b-hydroxysteroid dehydrogenase type 7-an ancient 3-ketosteroid reductase of cholesterogenesis. Mol. Cell. Endocrinol. 171, 199-204.
9. Campos, S.M. (2004). Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist 9, 126-136.
10. Chen, J., Wang, W.Q., and Lin, S.X. (2013). Interaction of Androst-5-ene-3b,17b-diol and 5a-androstane-3b,17b-diol with estrogen and androgen receptors: a combined binding and cell study. J. Steroid Biochem. Mol. Biol. 137, 316-321.
11. Dalvai, M., and Bystricky, K. (2010). Cell cycle and anti-estrogen effects synergize to regulate cell proliferation and ER target gene expression. PLoS One 5, e11011.
12. Day, J.M., Foster, P.A., Tutill, H.J., et al. (2008). 17b-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormonedependent breast cancer. Int. J. Cancer 122, 1931-1940.
13. Doisneau-Sixou, S.F., Sergio, C.M., Carroll, J.S., et al. (2003). Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr. Relat. Cancer 10, 179-186.
14. Duan, W.R., Parmer, T.G., Albarracin, C.T., et al. (1997). PRAP, a prolactin receptor associated protein: its gene expression and regulation in the corpus luteum. Endocrinology 138, 3216-3221.
15. Gangloff, A., Shi, R., Nahoum, V., et al. (2003). Pseudo-symmetry of C19 steroids, alternative binding orientations, and multispecificity in human estrogenic 17b-hydroxysteroid dehydrogenase. FASEB J. 17, 274-276.
16. Greeve, M.A., Allan, R.K., Harvey, J.M., et al. (2004). Inhibition of MCF-7 breast cancer cell proliferation by 5a-dihydrotestosterone; a role for p21Cip1/Waf1. J. Mol. Endocrinol. 32, 793-810.
17. Gutman, M., Couillard, S., Labrie, F., et al. (1999). Effects of the antiestrogen EM-800 (SCH 57050) and cyclophosphamide alone and in combination on growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res. 59, 5176-5180.
18. Han, P., Kang, J.H., Li, H.L., et al. (2009). Antiproliferation and apoptosis induced by tamoxifen in human bile duct carcinoma QBC939 cells via up regulated p53 expression. Biochem. Biophys. Res. Commun. 385, 251-256.
19. Hanamura, T., Niwa, T., Nishikawa, S., et al. (2013). Androgen metabolitedependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism. Breast Cancer Res. Treat. 139, 731-740.
20. Haynes, B.P., Straume, A.H., Geisler, J., et al. (2010). Intratumoral estrogen disposition in breast cancer. Clin. Cancer Res. 16, 1790-1801.
21. Hu, R., Dawood, S., Holmes, M.D., et al. (2011). Androgen receptor expression and breast cancer survival in postmenopausal women. Clin. Cancer Res. 17, 1867-1874.
22. Hur, J., Chesnes, J., Coser, K.R., et al. (2004). The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis. Proc. Natl Acad. Sci. USA 101, 2351-2356.
23. Jänicke, R.U. (2009). MCF-7 breast carcinoma cells do not express caspase-3. Breast Cancer Res. Treat. 117, 219-221.
24. Jemal, A., Bray, F., Center, M.M., et al. (2011). Global cancer statistics. CA Cancer J. Clin. 61, 69-90.
25. Jonat, W., Pritchard, K.I., Sainsbury, R., et al. (2006). Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient. J. Cancer Res. Clin. Oncol. 132, 275-286.
26. Jordan, V.C. (2003). Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug Discov. 2, 205-213.
27. Krazeisen, A., Breitling, R., Imai, K., et al. (1999). Determination of cDNA, gene structure and chromosomal localization of the novel human 17b-hydroxysteroid dehydrogenase type 7. FEBS Lett. 460, 373-379.
28. Labrie, F. (1991). Intracrinology. Mol. Cell. Endocrinol. 78, C113-C118.
29. Labrie, F. (2003). Extragonadal synthesis of sex steroids: intracrinology. Ann. Endocrinol. 64, 95-107.
30. Lanzino, M., Sisci, D., Morelli, C., et al. (2010). Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells - identification of a novel androgen response element. Nucleic Acids Res. 38, 5351-5365.
31. Laplante, Y., Cadot, C., Fournier, M.A., et al. (2008). Estradiol and estrone C-16 derivatives as inhibitors of type 117b-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone. Bioorg. Med. Chem. 16, 1849-1860.
32. Laplante, Y., Rancourt, C., and Poirier, D. (2009). Relative involvement of three 17b-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors. Mol. Cell. Endocrinol. 301, 146-153.
33. Liehr, J.G. (2000). Is estradiol a genotoxic mutagenic carcinogen? Endocr. Rev. 21, 40-54.
34. Lin, S.X., Chen, J., Mazumdar, M., et al. (2010). Molecular therapy of breast cancer: progress and future directions. Nat. Rev. Endocrinol. 6, 485-493.
35. Lin, S.X., Poirier, D., and Adamski, J. (2013). A challenge for medicinal chemistry by the 17b-hydroxysteroid dehydrogenase superfamily: an integrated biological function and inhibition study. Curr. Top. Med. Chem. 13, 1164-1171.
36. Marijanovic, Z., Laubner, D., Moller, G., et al. (2003). Closing the gap: identification of human3-ketosteroid reductase, the last unknown enzyme of mammalian cholesterol biosynthesis. Mol. Endocrinol. 17, 1715-1725.
37. Martin, L.A., and Dowsett, M. (2013) BCL-2: anewtherapeutic target in estrogen receptor-positive breast cancer? Cancer Cell 24, 7-9.
38. Miller, W.R., and Larionov, A.A. (2012). Understanding the mechanisms of aromatase inhibitor resistance. Breast Cancer Res. 14, 201.
39. Neve, R.M., Chin, K., Fridlyand, J., et al. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10, 515-527.
40. Niemeier, L.A., Dabbs, D.J., Beriwal, S., et al. (2010). Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod. Pathol. 23, 205-212.
41. Nokelainen, P., Peltoketo, H., Vihko, R., et al. (1998). Expression cloning of a novel estrogenic mouse 17b-hydroxysteroid dehydrogenase/17-ketosteroid reductase (m17HSD7), previously described as a prolactin receptorassociated protein (PRAP) in rat. Mol. Endocrinol. 12, 1048-1059.
42. Ohnesorg, T., Keller, B., HrabédeAngelis, M., et al. (2006). Transcriptional regulation of human and murine 17b-hydroxysteroid dehydrogenase type-7 confers its participation in cholesterol biosynthesis. J. Mol. Endocrinol. 37, 185-197.
43. Pasqualini, J.R. (2004). The selective estrogen enzyme modulators in breast cancer: a review. Biochim. Biophys. Acta 1654, 123-143.
44. Pasqualini, J.R., Chetrite, G., Blacker, C., et al. (1996). Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre-and post-menopausal breast cancer patients. J. Clin. Endocrinol. Metab. 81, 1460-1464.
45. Payne, A.H., and Hales, D.B. (2004). Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr. Rev. 25, 947-970.
46. Pearson, O.H., Manni, A., and Arafah, B.M. (1982). Antiestrogen treatment of breast cancer: an overview. Cancer Res. 42, 3424-3429.
47. Poirier, D. (2010). 17b-Hydroxysteroid dehydrogenase inhibitors: a patent review. Expert Opin. Ther. Pat. 20, 1123-1145.
48. Quent, V.M., Loessner, D., Friis, T., et al. (2010). Discrepancies betweenmetabolic activity and DNA content as tool to assess cell proliferation in cancer research. J. Cell. Mol. Med. 14, 1003-1013.
49. Rhodes, D.R., Yu, J., Shanker, K., et al. (2004). ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6, 1-6.
50. Ring, A., and Dowsett, M. (2004). Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer 11, 643-658.
51. Rixe, O., and Fojo, T. (2007). Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? Clin. Cancer Res. 13, 7280-7287.
52. Russo, I.H., and Russo, J. (1998). Role of hormones in mammary cancer initiation and progression. J. Mammary Gland Biol. Neoplasia 3, 49-61.
53. Shehu, A., Mao, J., Gibori, G.B., et al. (2008). Prolactin receptor-associated protein/17b-hydroxysteroid dehydrogenase type 7 gene (Hsd17b7) plays a crucial role in embryonic development and fetal survival. Mol. Endocrinol. 22, 2268-2277.
54. Shehu, A., Albarracin, C., Devi, Y.S., et al. (2011). The stimulation of HSD17B7 expression by estradiol provides a powerful feed-forward mechanism for estradiol biosynthesis in breast cancer cells. Mol. Endocrinol. 25, 754-766.
55. Sikora, M.J., Cordero, K.E., Larios, J.M., et al. (2009). The androgen metabolite 5a-androstane-3b,17b-diol (3bAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance. Breast Cancer Res. Treat. 115, 289-296.
56. Stanway, S.J., Purohit, A., Woo, L.W., et al. (2006). Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin. Cancer Res. 12, 1585-1592.
57. Thiantanawat, A., Long, B.J., and Brodie, A.M. (2003). Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res. 63, 8037-8050.
58. Törn, S., Nokelainen, P., Kurkela, R., et al. (2003). Production, purification, and functional analysis of recombinanthuman andmouse 17b-hydroxysteroid dehydrogenase type 7. Biochem. Biophys. Res. Commun. 305, 37-45.
59. Vera-Badillo, F.E., Templeton, A.J., de Gouveia, P., et al. (2014). Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J. Natl Cancer Inst. 106, 319.
60. Williams, S.J. (2013). Sulfatase inhibitors: a patent review. Expert Opin. Ther. Pat. 23, 79-98.
61. Woolcott, C.G., Shvetsov, Y.B., Stanczyk, F.Z., et al. (2010). Plasma sex hormone concentrations and breast cancer risk in an ethnically diverse population of postmenopausal women: the Multiethnic Cohort Study. Endocr. Relat. Cancer 17, 125-134.
62. Wu, H., Chen, Y., Liang, J., et al. (2005). Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 438, 981-987.
63. Yager, J.D., and Davidson, N.E. (2006). Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354, 270-282.